EMG
IOVA icon

ETF Managers Group’s Iovance Biotherapeutics IOVA Stock Holding History

ETF Managers Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-114,431
Closed -$1.25M – 756
2022
Q2 		$1.25M Buy
+114,431
New +$1.5M 0.04% 213

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

ETF Managers Group's IOVA Position: Q3 2022 in Review

ETF Managers Group sold out of Iovance Biotherapeutics (IOVA) in Q3 2022, closing a stake of 114,431 shares — an estimated $1.25M sold.

ETF Managers Group first reported a position in IOVA in Q2 2022 and held it in 1 quarter. The position peaked at $1.25M in Q2 2022. 242 funds tracked by Wall St. Rank hold IOVA as of Q3 2022.

  • ETF Managers Group reported no remaining Iovance Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • ETF Managers Group sold 114,431 Iovance Biotherapeutics shares in Q3 2022, an estimated $1.25M.
  • ETF Managers Group first reported a position in Iovance Biotherapeutics in Q2 2022 and held it in 1 quarter.
  • ETF Managers Group's Iovance Biotherapeutics position peaked at $1.25M in Q2 2022.
  • 242 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2022.

Based on ETF Managers Group's 13F filing for Q3 2022, filed 14 Nov 2022.